Higher Cytogenetic Response Rates

With Gleevec�*

Major Cytogenetic Response� Complete Cytogenetic Response�

0

20

40

60

80

100

Gleevec IFN-α +

ara-C

% of Patients

0

20

40

60

80

100

Gleevec IFN-α +

ara-C

% of Patients

76%�

12%

54%�

3%

�P<0.001. Confirmed responses shown.

Unconfirmed MCR�Gleevec: 83%; IFN-α + ara-C: 20%.

Unconfirmed CCR�Gleevec: 68%; IFN-α + ara-C: 7%.

*IRIS Study; n=553 in each arm.

�≤35% Ph+ cells.

�0% Ph+ cells.

For important safety information, please see

slide 3 or full Prescribing Information.

[Slide 15]

Higher Cytogenetic Response Rates With Gleevec�1,2

� The data were analyzed using Fischer�s Exact Test.

� A statistically significantly higher percentage of patients achieved a major cytogenetic response (≤35% Ph+ cells) with Gleevec (76% confirmed, 83% unconfirmed) versus IFN-α

+ ara-C (12% confirmed, 20% unconfirmed); P<0.001.

� A statistically significantly higher percentage of patients achieved a complete cytogenetic

response (0% Ph+ cells) with Gleevec (54% confirmed, 68% unconfirmed) versus IFN-α + ara-C

(3% confirmed, 7% unconfirmed); P<0.001.

� Confirmed responses were observed on 2 occasions ≥4 weeks apart; unconfirmed responses

were observed on 1 occasion.

References

1. Gleevec� (imatinib mesylate) Prescribing Information. East Hanover, NJ: Novartis

Pharmaceuticals Corporation; 2003.

2. Data on file. Novartis Pharmaceuticals Corporation, East Hanover, NJ.